Home > Healthcare > Biotechnology > Biopharma > Carcinoembryonic Antigen (CEA) Market

Carcinoembryonic Antigen (CEA) Market Share

Report ID: GMI427
Published Date: Sep 2024
Report Format: PDF

Download Free Sample

CEA Market Share

The market is driven by intense competition among key players such as F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., and Quest Diagnostics. These companies leverage their extensive portfolios and strong distribution networks while investing in R&D to enhance the accuracy and cost-effectiveness of CEA tests. Emerging companies are also contributing to market growth through innovations in point-of-care diagnostics and immunoassays. Additionally, the increasing emphasis on early cancer detection and monitoring, coupled with technological advancements, is propelling market demand, creating opportunities for both established and emerging players.

Carcinoembryonic Antigen Market Companies

Few of the prominent players operating in the carcinoembryonic antigen industry include:

Abcam Limited.
AdvaCare Pharma
Aviva Systems Biology Corporation
Boster Biological Technology
Creative Diagnostics
Diazyme Laboratories Inc.
F. Hoffmann-La Roche Ltd.
Medix Biochemica
Omega Diagnostics Ltd.
RayBiotech, Inc.
Thermo Fisher Scientific Inc.
Quest Diagnostics Incorporated

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global carcinoembryonic antigen industry was valued at USD 2.2 billion In 2023 and is projected to grow at a 6.3% CAGR from 2024 to 2032, driven by the increasing prevalence of various cancers, including colorectal, lung, and breast cancers.

The gastrointestinal cancer segment led the market with a 41.4% share in 2023 and is expected to maintain its dominance with a CAGR of 6.7% during the forecast period.

The U.S. market's prominence is attributed to its advanced healthcare infrastructure, a high prevalence of gastrointestinal cancers, and robust research initiatives. In 2023, the U.S. market in North America was valued at USD 830.1 million and is anticipated to show considerable growth over the analysis period.

Prominent players in the industry include Abcam Limited, AdvaCare Pharma, Aviva Systems Biology Corporation, Boster Biological Technology, Creative Diagnostics, Diazyme Laboratories Inc., F. Hoffmann-La Roche Ltd., Medix Biochemica, Omega Diagnostics Ltd., RayBiotech, Inc., Thermo Fisher Scientific Inc., and Quest Diagnostics Incorporated.